JP2022507506A5 - - Google Patents

Info

Publication number
JP2022507506A5
JP2022507506A5 JP2021526492A JP2021526492A JP2022507506A5 JP 2022507506 A5 JP2022507506 A5 JP 2022507506A5 JP 2021526492 A JP2021526492 A JP 2021526492A JP 2021526492 A JP2021526492 A JP 2021526492A JP 2022507506 A5 JP2022507506 A5 JP 2022507506A5
Authority
JP
Japan
Prior art keywords
alkyl
membered
aryl
alkoxy
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021526492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507506A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061533 external-priority patent/WO2020102576A1/en
Publication of JP2022507506A publication Critical patent/JP2022507506A/ja
Publication of JP2022507506A5 publication Critical patent/JP2022507506A5/ja
Pending legal-status Critical Current

Links

JP2021526492A 2018-11-16 2019-11-14 Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 Pending JP2022507506A (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201862768804P 2018-11-16 2018-11-16
US62/768,804 2018-11-16
US201862769151P 2018-11-19 2018-11-19
US201862769165P 2018-11-19 2018-11-19
US62/769,165 2018-11-19
US62/769,151 2018-11-19
US201962795913P 2019-01-23 2019-01-23
US62/795,913 2019-01-23
US201962796361P 2019-01-24 2019-01-24
US201962796356P 2019-01-24 2019-01-24
US62/796,356 2019-01-24
US62/796,361 2019-01-24
US201962802621P 2019-02-07 2019-02-07
US62/802,621 2019-02-07
US201962895954P 2019-09-04 2019-09-04
US62/895,954 2019-09-04
PCT/US2019/061533 WO2020102576A1 (en) 2018-11-16 2019-11-14 Compounds and compositions for treating conditions associated with nlrp activity

Publications (2)

Publication Number Publication Date
JP2022507506A JP2022507506A (ja) 2022-01-18
JP2022507506A5 true JP2022507506A5 (https=) 2022-11-21

Family

ID=68808610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526492A Pending JP2022507506A (ja) 2018-11-16 2019-11-14 Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物

Country Status (6)

Country Link
US (1) US20230051589A1 (https=)
EP (1) EP3880659B1 (https=)
JP (1) JP2022507506A (https=)
CN (1) CN113286784A (https=)
TW (1) TW202033504A (https=)
WO (1) WO2020102576A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3823974A1 (en) 2018-07-20 2021-05-26 F. Hoffmann-La Roche AG Sulfonimidamide compounds as inhibitors of interleukin-1 activity
EP4093509A1 (en) * 2020-01-22 2022-11-30 F. Hoffmann-La Roche AG Sulfonimidamide compounds as nlrp3 modulators
EP3984535A1 (en) * 2020-10-16 2022-04-20 Albert-Ludwigs-Universität Freiburg Nlrp3 activators for use in the treatment of infectious diseases or cancer by activating nlrp3 inflammasome
CN114539256B (zh) * 2020-11-20 2024-02-02 上海拓界生物医药科技有限公司 三环化合物及其医药用途
JP7825294B2 (ja) * 2021-02-10 2026-03-06 ハンジョウ イノゲート ファーマ カンパニー リミテッド Ｎｌｒｐ３阻害剤としての化合物
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN118302415A (zh) * 2021-12-03 2024-07-05 辰欣药业股份有限公司 二甲基亚磺酰亚胺衍生物的制备方法
CN116804018A (zh) * 2022-03-25 2023-09-26 成都百裕制药股份有限公司 酰胺衍生物及其制备方法和在医药上的应用
CN114989058B (zh) * 2022-06-02 2024-04-16 中国科学院成都生物研究所 一种手性氯代砜亚胺类化合物及其衍生物的制备方法
EP4561574A1 (en) * 2022-07-27 2025-06-04 Novartis AG Dosing regimen for a nlrp3 inhibitor
CN115961298B (zh) * 2022-12-31 2024-10-01 广西师范大学 一种电化学介导乙烯基苯胺与醇合成2，3-二烷氧基取代吲哚啉化合物、合成方法及应用
PE20252770A1 (es) * 2023-03-17 2025-12-22 Ventus Therapeutics U S Inc Derivados de amida para inhibir nlrp3 y usos de estos
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102727059B1 (ko) * 2015-02-16 2024-11-05 더 유니버서티 어브 퀸슬랜드 설포닐우레아와 관련 화합물 및 그 용도
FR3046933B1 (fr) * 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
EP3634951B8 (en) * 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
RS65492B1 (sr) * 2017-07-24 2024-05-31 Novartis Ag Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp
US11623922B2 (en) * 2017-10-03 2023-04-11 Inflazome Limited Compounds
EP3823974A1 (en) * 2018-07-20 2021-05-26 F. Hoffmann-La Roche AG Sulfonimidamide compounds as inhibitors of interleukin-1 activity

Similar Documents

Publication Publication Date Title
JP2022507506A5 (https=)
JP2022505525A5 (https=)
JP2020528889A5 (https=)
JP2022507065A5 (https=)
JP2019519598A5 (https=)
JP2019518071A5 (https=)
JP2020537657A5 (https=)
JP2019515952A5 (https=)
AU2020200979B2 (en) New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
JP2022506898A5 (https=)
JP2022507505A5 (https=)
US11058678B2 (en) Substituted heterocycles as antiviral agents
JP6411492B2 (ja) 多環式カルバモイルピリドン化合物およびｈｉｖ感染症を処置するためのその使用
CN112047927A (zh) 展现抗癌和抗增殖活性的n-酰基-n′-(吡啶-2-基)脲及类似物
KR102817726B1 (ko) 면역 조절제
AU2017254523A1 (en) Compounds and compositions for treating conditions associated with NLRP activity
EP3252058A1 (en) Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
UA129653C2 (uk) Макроциклічна сполука як агоніст sting, спосіб з її застосуванням і шлях її застосування
JP2023509495A (ja) ＲＯＲγｔ阻害剤、その製造方法及び使用
DE69905451T2 (de) Neue triazolo(4,5d) pyrimidinverbindungen
JP2016503005A (ja) 腫瘍始原細胞を除去するための薬剤
EP2573090B1 (en) (6,7-dihydro-2-nitro-5h-imidazol[2,1-b][1,3]oxazin-6-yl) amide compounds, preparation methods and uses thereof
CN105051046A (zh) β-氨基羰基类化合物、其制备方法、药物组合物及其用途
CN102858769A (zh) 吡唑并吡啶激酶抑制剂
JP2008542377A5 (https=)